Clinical Trial: TQB2223 Injection in Combination With Penpulimab in Patients With Advanced Cancers
Study Status: Completed
Recruit Status: RECRUITING
Condition: Advanced Cancer
Study Type: INTERVENTIONAL
Official Title: Phase I Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of TQB2223 Injection Combined With Penpulimab Injection in Subjects With Advanced Cancers
Brief Summary:
TQB2223 is a recombinant, fully humanized antibody that binds lymphocyte activation gene-3 (LAG-3) and blocks the LAG-3/ major histocompatibility complex class II (MHC-II) interaction, thus allowing for increased T-cell proliferation and cytokine production.This is a phase I study to evaluate the safety, tolerability, pharmacokinetics (PK) and effectiveness of TQB2223 injection in combination with Penpulimab in subjects with advanced cancers.
Read more